Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Desvenlafaxine SR Extension Study in Pediatric MDD
NCT01371721Phase 3Completed
- Sponsor
- Pfizer
- Start
- Feb 2012
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of desvenlafaxine in major depressive disorder (MDD), sponsored by Pfizer. Primary endpoint: Treatment Emergent Adverse Events at 26 weeks. Started Feb 2012; status: completed.
02
Drugs
desvenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01371721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01371721.